Stonegate Capital Partners has updated its coverage on Burcon Nutrascience Corporation (TSX: BU), following the company's fiscal first-quarter 2027 results. The announcement underscores a pivotal shift from technology validation to commercial execution, as revenue increased 54% sequentially and 273% year-over-year to $1.28 million. Active buying customers grew to 40 from over 30 previously, and repeat purchasing continues to build, providing improved visibility into recurring demand.
The quarter's results were clouded by a $1.76 million inventory write-down, which masked a much narrower underlying gross loss. This suggests that the core business is improving operationally, even as the company manages one-time charges. The focus now shifts to whether Burcon can sustain this customer traction and execute on its capacity expansion plans to achieve the significant second-half revenue ramp required to meet its prior CY26 sales objective of $10 million. To reach that target, the company would need approximately $7.9 million in second-half sales, a substantial increase from current run rates.
Key execution levers include capacity and funding. Burcon has planned an up-to-$8.1 million financing to bridge liquidity and support the expansion of its Galesburg facility. This capital is critical to scale production and meet anticipated demand. The company's path to positive cash flow remains an important milestone, and the upcoming quarters will be telling in terms of whether the sales momentum can be maintained and accelerated.
For more details, refer to the full announcement.
